One important metric to look for in a stock is an 80 or higher Relative Strength Rating. Disc Medicine cleared that benchmark Wednesday, with a jump from 77 to 81 Wednesday.
Hone Your Stock-Picking Skills By Focusing On These Factors
IBD's unique RS Rating tracks market leadership by using a 1 (worst) to 99 (best) score that identifies how a stock's price action over the last 52 weeks matches up against other publicly traded companies.
History reveals that the best stocks tend to have an RS Rating of over 80 in the early stages of their moves.
While it's not currently an ideal time to invest, see if the stock is able to offer and clear a proper buy point.
Disc Medicine reported 0% earnings growth last quarter. Revenue gains came in at 0%.
The company earns the No. 169 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Halozyme Therapeutics and Rigel Pharmaceuticals are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Improved Price Performance?
